- EYPT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-K/A Filing
EyePoint Pharmaceuticals (EYPT) 10-K/A2017 FY Annual report (amended)
Filed: 30 Oct 17, 12:00am
Exhibit 31.1
Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule15d-14(a) of the Securities Exchange Act of 1934, as amended.
CERTIFICATIONS
I, Nancy Lurker, certify that:
1. | I have reviewed this Amendment to the Annual Report on Form10-K of pSivida Corp.for the fiscal year ended June 30, 2017; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
Date: October 30, 2017
/s/ Nancy Lurker |
Name: Nancy Lurker |
Title: President and Chief Executive Officer |
(Principal Executive Officer) |